Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD

Qiukui Hao; Gordon Guyatt

doi:10.7326/ACPJ202101190-011

Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD

Ann Intern Med. 2021 Jan;174(1):JC11. doi: 10.7326/ACPJ202101190-011. Epub 2021 Jan 5.

Authors

Qiukui Hao¹, Gordon Guyatt²

Affiliations

¹ The Center of Gerontology and Geriatrics/National Clinical Research Center for Geriatrics West China Hospital, Sichuan University, Chengdu, Sichuan, China (Q.H.).
² McMaster University, Hamilton, Ontario, Canada (G.G.).

PMID: 33395335
DOI: 10.7326/ACPJ202101190-011

Abstract

Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. 32843476.

Publication types

Comment

MeSH terms

Aged
Amputation, Surgical
Canagliflozin / adverse effects
Cardiovascular Diseases* / epidemiology
Cohort Studies
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide 1
Heart Disease Risk Factors
Humans
Hypoglycemic Agents / adverse effects
Retrospective Studies
Risk Factors

Substances

Hypoglycemic Agents
Canagliflozin
Glucagon-Like Peptide 1